Litcius/Paper detail

Safety and efficacy of satralizumab monotherapy in neuromyelitis optica spectrum disorder: a randomised, double-blind, multicentre, placebo-controlled phase 3 trial

Anthony Traboulsee, Benjamin Greenberg, Jeffrey L. Bennett, L Szczechowski, Edward Fox, Svitlana Shkrobot, Takashi Yamamura, Yusuke Terada, Yuichi Kawata, Pádraig Wright, Athos Gianella-Borradori, Hideki Garren, Brian G. Weinshenker

2020The Lancet Neurology491 citationsDOIOpen Access PDF

Topics & Concepts

MedicinePlaceboClinical endpointPopulationNeuromyelitis opticaInternal medicineClinical trialIntention-to-treat analysisPediatricsAntibodyImmunologyPathologyEnvironmental healthAlternative medicineMultiple Sclerosis Research StudiesPeripheral Neuropathies and DisordersSystemic Sclerosis and Related Diseases
Safety and efficacy of satralizumab monotherapy in neuromyelitis optica spectrum disorder: a randomised, double-blind, multicentre, placebo-controlled phase 3 trial | Litcius